Page 6 - CANNABIDIOL (CBD) Critical Review Report Geneva, 4-7 June 2018 World Health Organization

40th ECDD (2018) Agenda item 4.1 Cannabidiol (CBD)

Summary

Cannabidiol (CBD) is one of the naturally occurring cannabinoids found in cannabis plants. It
is a 21-carbon terpenophenolic compound which is formed following decarboxylation from a
cannabidiolic acid precursor, although it can also be produced synthetically.

In experimental models of abuse liability, CBD appears to have little effect on conditioned
place preference or intracranial self-stimulation. In an animal drug discrimination model CBD
failed to substitute for THC. In humans, CBD exhibits no effects indicative of any abuse or
dependence potential.

CBD has been demonstrated as an effective treatment of epilepsy in several clinical trials, with
one pure CBD product (Epidiolex®) with completed Phase III trials and under current
review for approval in the U.S. There is also preliminary evidence that CBD may be a useful
treatment for a number of other medical conditions.

There is unsanctioned medical use of CBD based products with oils, supplements, gums, and
high concentration extracts available online for the treatment of many ailments.

CBD is generally well tolerated with a good safety profile. Reported adverse effects may be as
a result of drug-drug interactions between CBD and patients’ existing medications.

Several countries have modified their national controls to accommodate CBD as a medicinal
product.

To date, there is no evidence of recreational use of CBD or any public health-related problems
associated with the use of pure CBD.

5